Clinical Alert from The National Heart, Lung, and Blood Institute (NHLBI)

Commonly Used Three-drug Regimen for Idiopathic Pulmonary Fibrosis Found Harmful.

The National Heart, Lung and Blood Institute (NHLBI), part of the National Institutes of Health, has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis (IPF) for safety concerns.

The trial found that people with IPF receiving a currently used triple-drug therapy consisting of prednisone, azathioprine, and N-acetylcysteine (NAC) had worse outcomes than those who received placebos or inactive substances.

Detailed information on this clinical alert can be found at: http://www.nlm.nih.gov/databases/alerts/2011_nhlbi_ifp.html

New Database: Health Research Funding

Health Research Funding, is a new database developed by the National Health Council (NHC) with input from the National Institutes of Health (NIH). The database is designed to bring researchers with peer-reviewed, worthwhile unfunded projects together with patient advocacy organizations and other funding resources.

The goal of this site is to foster the funding of new research that will provide hope to millions of people in this country with chronic diseases and disabilities.

Researchers with promising projects that have been scored but not funded by the NIH or Researchers with proposals that have been peer-reviewed but not funded by a NHC member patient advocacy organization, are encouraged to apply.

For more information visit: http://healthresearchfunding.org/

Clinical Alert

The National Institute of Neurological Disorders and Stroke (NINDS) Issues New Clinical Alert on Angioplasty Combined with Stenting Plus Aggressive Medical Therapy vs. Aggressive Medical Therapy Alone for Intracranial Arterial Stenosis: NINDS Stops Trial Enrollment Due to a Higher Risk of Stroke and Death in the Stented GroupLink:  http://www.nlm.nih.gov/databases/alerts/clinical_alerts.html

______________________________________________________________________________